Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for AUROPHARMA
Revenue projections for AUROPHARMA

Investors are expected to be cautious with Aurobindo Pharma Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 1.850000
forwardPE 14.705329
debtToEquity 25.310000
earningsGrowth 0.003000
revenueGrowth 0.106000
grossMargins 0.589380
operatingMargins 0.160760
trailingEps 59.800000
forwardEps 62.290000

The current ratio for AUROPHARMA is 1.85, indicating that the company can service its short-term debt using available cash and assets. This suggests AUROPHARMA has strong liquidity, with more than enough resources to meet its immediate financial commitments.
AUROPHARMA's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
AUROPHARMA's low Debt-to-Equity ratio reflects limited reliance on debt, signaling the company is not over-leveraged. This lower financial risk suggests that AUROPHARMA has a strong capital structure, which can help sustain long-term stability and attract cautious investors.
Aurobindo Pharma Limited's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for AUROPHARMA
Price projections for AUROPHARMA

Price projections for AUROPHARMA have been steadily revised downward over time, indicating growing concerns about the company's future performance. This downward trend reflects reduced optimism among analysts regarding AUROPHARMA's ability to meet previous expectations.

Recommendation changes over time:

Recommendations trend for AUROPHARMA
Recommendations trend for AUROPHARMA


Analysts have maintained a buy bias for Aurobindo Pharma Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Aurobindo Pharma Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.